Jawaid Jamal, MD
Nephrology · Oklahoma City, OKNPI 1417948886
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 331 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations.
Across 331 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$910
- Travere Therapeutics, Inc.$821
- Fresenius USA Marketing, Inc.$625
- Novartis$555
- Amgen$520
- Vifor Pharma, Inc.$458
- plus $3K from 29 others
What the payments were for
- Food & beverage$6,57699%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 47 | $910 |
| Travere Therapeutics, Inc. | 34 | $821 |
| Fresenius USA Marketing, Inc. | 51 | $625 |
| Novartis | 22 | $555 |
| Amgen(2 entities) | 26 | $520 |
| Vifor Pharma, Inc. | 22 | $458 |
| Bayer | 19 | $298 |
| Aurinia Pharma U.S., Inc. | 15 | $292 |
| Madrigal Pharmaceuticals | 2 | $262 |
| OPKO Pharmaceuticals, LLC | 10 | $194 |
| Novo Nordisk | 9 | $162 |
| GSK | 10 | $156 |
| Daiichi Sankyo Inc. | 7 | $136 |
| Otsuka America Pharmaceutical, Inc. | 7 | $132 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 6 | $129 |
| AbbVie | 1 | $109 |
| Ardelyx, Inc. | 5 | $90 |
| Gilead | 1 | $86 |
| Mallinckrodt Hospital Products Inc. | 4 | $85 |
| Calliditas Therapeutics US Inc. | 4 | $75 |
| Boehringer Ingelheim | 4 | $65 |
| Veloxis Pharmaceuticals, Inc. | 3 | $60 |
| ANI Pharmaceuticals, Inc. | 3 | $59 |
| Pharmacosmos Therapeutics Inc. | 3 | $58 |
| Genentech USA, Inc. | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| La Jolla Pharmaceutical Company | 2 | $37 |
| Shield Therapeutics Inc | 1 | $36 |
| Mallinckrodt Enterprises LLC | 2 | $26 |
| Medtronic | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Angiodynamics, Inc. | 1 | $16 |
| Akebia Therapeutics Inc | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESMETIROM$146
- REZDIFFRA$116
- Mavyret$109
How this compares
$6,621 in reported general payments places this provider in the 80th percentile of 106 nephrology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 16 | $83,256 |
| FarxigaDapagliflozin Propanediol | 45 | $33,264 |
| Sevelamer Carbonate | 34 | $9,159 |
| Clonidine | 16 | $2,979 |
| Calcitriol | 75 | $1,576 |
| Hydralazine Hcl | 52 | $1,050 |
| Amlodipine Besylate | 103 | $909 |
| Losartan Potassium | 51 | $688 |
| Nifedipine ErNifedipine | 16 | $612 |
| Furosemide | 61 | $458 |
| Torsemide | 16 | $372 |
| Potassium Chloride | 21 | $367 |
| Carvedilol | 24 | $363 |
| Doxazosin Mesylate | 26 | $324 |
| Allopurinol | 21 | $203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $625 | $83,25616 claims |
| AstraZenecaFarxiga | $910 | $33,26445 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 106 nephrology providers in Oklahoma.
Other nephrology in Oklahoma City
- Celeste BoeckmanOklahoma City$90K
- Joseph GhataOklahoma City$45K
- Benjamin CowleyOklahoma City$36K
- Brad CarterOklahoma City$13K
- Laura RankinOklahoma City$11K
- Gary BondOklahoma City$9K
- Sudhir KhannaOklahoma City$7K
- Patrick ReevesOklahoma City$6K
- Bradley LongOklahoma City$6K
- Chris SholerOklahoma City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.